PPD, Inc. will acquire BioDuro, a preclinical CRO, as a follow-up to its purchase last month of Excel PharmaStudies, both of which are major transactions; we reflected on the huge difference between how China and the US go about creating “life science clusters”; China enrolled a record number of students in American universities during 2008-9; China Cord Blood listed on the NYSE and also completed a secondary offering; Advanced BioMedical signed an agreement in China to develop its bio-absorbable material in new applications; China Medicine Corp. found investors who may put $59.5 million in the company; Jennerex licensed the China rights for its novel cancer drug to Lee’s Pharma; a wound healing product made by Oculus was approved for animal use; GlaxoSmithKline will begin manufacturing its treatment for flu, Relenza, in China; Goldman Sachs said Pfizer will see $3 billion of China sales in 2012; WuXi PharmaTech (????) reported a modest increase in Q3 revenues and raised guidance; Sinovac Biotech (????????????) released a stellar Q3 report due to flu vaccine revenues; Tongjitang Chinese Medicines (?????) continues to report declining sales; and American Oriental Bioengineering (??????) said Q3 revenues rose 12% but net income fell 39%. More details...

Stock Symbols: (NSEQ: PPDI) (NYSE: CO) (OTCBB: ABMT) (OTCBB: CHME) (NSDQ: OCLS) (NYSE: GSK) (NYSE: PFE)  (NYSE: WX) (NSDQ: SVA) (NYSE: TCM) (NYSE: AOB)

PRG-Schultz International, Inc. (NASDAQ: PRGX) rose 8.42% to $5.28 in the pre-market session. The 52 week trading range for PRGX is $2.48 - $6.98. In the last six months, PRGX is up 67%.

Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) climbed 5.37% to $10.80. Yesterday ENZN made a new high at $10.33 and closed at $10.25 after breaking its previous 52 week high. So far this year, ENZN is up 75%.

NetApp Inc. (NASDAQ: NTAP) is currently trading at $30.81, moving up by 4.32% after Brigantine Advisors made a Hold rating on NetApp, increasing its price target to $32 from $30 as analysts feels that NetApp will show a growth in its top line. NetApp also reported stronger results for the October quarter.

Sears Holdings Corporation (NASDAQ: SHLD) today reported third-quarter net loss of $127 million, or $1.09 per share and adjusted loss of $0.81 per share. While, revenue was $10.19 billion, a decrease of 4% same quarter last year. Analysts on an average expected a loss of $1.09 a share on revenue of $9.92 billion. In the pre-market session, Sears Holdings Corporation (NASDAQ: SHLD) is trading up 3.63% at $78.52. So far in the current year, SHLD gained over 94%.

Geron Corporation (NASDAQ: GERN) jumped 2.88% to $6.08 after it posted a higher quarterly profit that beat estimates by , boosted by .The 52 week trading range for GERN is $2.48 - $9.24. Yesterday GERN closed at $5.91. In the last six months, GERN fell by around 8%.

Sinovac Biotech Ltd. (NASDAQ: SVA) moved up 1.95% to $7.70 in the pre-market. Yesterday, Brean Murray gave Sinovac Biotech (NYSE: SVA) a Buy rating at price target of $11. On yesterday’s closing price of $7.70, SVA shows a premium of over 35% on Murray’s price target of $11.

Solarfun Power Holdings Co., Ltd. (ADR) (NASDAQ: SOLF) surged 2% to $6.61. Yesterday Solarfun Power reported its third quarter profit CNY136.6 million or CNY 2.53 an American depositary share while analysts polled by Thomson Reuters expected SOLF to report 15 cent profit. Solarfun Power Holdings Co., Ltd. (ADR) (NASDAQ: SOLF) is currently trading at $6.58, increased by 2% in the pre-market session. In the last six months, SOLF gained over 27%.

EpiCept Corporation (Nasdaq:EPCT) announced a Nasdaq Hearings Panel has granted the Company’s request for continued listing on The Nasdaq Stock Market.

GenVec, Inc. (Nasdaq:GNVC) announced Paul H. Fischer, Ph.D., President and CEO, will present a company overview highlighting recent developments at the Merriman Curhan Ford's 6th Annual Investor Summit on Tuesday, November 10, 2009 at 9:20 am EST at Sofitel Hotel in New York, NY.

Enzon Pharmaceuticals, Inc. (Nasdaq:ENZN) announced its third quarter 2009 financial results. For the three months ended September 30, 2009, Enzon reported a net income of $0.1 million or break-even on a diluted per-share basis, as compared to a net loss of $2.0 million or $0.05 on a diluted per-share basis for the third quarter of 2008.

ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced Jonathan Lewis, MD, PhD, Chief Executive Officer, will present at the 6th Annual Merriman, Curhan, Ford Investor Summit on Tuesday, November 10, 2009 at 12:20 pm ET at the Soffitel Hotel in New York, NY. Dr. Lewis will provide an overview of the Company and its clinical development programs.

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) reported results for the quarter ended September 30, 2009.

Aetna (NYSE:AET) is providing free electronic roster billing for pharmacies and other non-traditional providers to use when submitting claims for the administration of the H1N1 flu vaccine.

Stem Cell Therapy International Inc. (OTC:SCII) and its soon to be subsidiary, Histostem Ltd. of South Korea ("Histostem"), announced they have entered into a definitive agreement for up to a $5 million investment commitment with Socius Life Science Capital Group, LLC.The Company's plan is to have funds available no later than December 31, 2009 and use the proceeds for various growth initiatives, including the launch of its stem cell based facial cream, the initiation of clinical trials, maintaining and advancement of current GMP facility as well as ongoing working capital and general corporate purposes.

NanoLogix, Inc. (OTC:NNLX), announces the company has recently filed BNP™ (BioNanoPore) national patent applications in China, Japan, India, Brazil, Russia and the EU.

Sinovac Biotech Ltd. (NYSE:SVA), a leading developer and provider of vaccines in China, announced it will voluntarily transfer its stock exchange listing from the NYSE Amex to the NASDAQ Global Market.

Solos Endoscopy, Inc. (OTC:SNDY) is pleased to announce the Company has received purchase orders for its MammoView(TM) line of surgical endoscopy instruments from various hospitals under Catholic Health Initiatives, Littleton, CO.

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,612,199 (the ‘199 patent) entitled “Polymorphic Forms Alpha, Beta, and Gamma of Rifaximin”.

Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) announced Robert Perez, EVP and COO, will present on Wednesday, November 18, 2009 at 1:45 p.m. Eastern Time at the Lazard Capital Markets 6th Annual Healthcare Conference at the St Regis Hotel in New York City.

Merck & Co., Inc. (NYSE:MRK) and Schering-Plough Corporation (NYSE:SGP) announced they will complete their merger shortly after 4:00PM ET.

Advanced Cell Technology, Inc. (OTC:CTC) announced its Chief Executive Officer, William Caldwell, IV, presented at the BIO Europe Conference being held in Vienna, Austria.

Catalyst Health Solutions, Inc. (NASDAQ:CHSI), a pharmacy benefit management company, announced its financial results for the third quarter ended September 30, 2009.

Optigenex Inc. (OTC:OPGX), has unveiled a new information web page www.optigenex.com designed to connect with prospective corporate customers and partners in the wellness and personal care industries.

Walgreens (NYSE:WAG) executive vice president and chief financial officer Wade Miquelon will present during the Credit Suisse Annual Healthcare Conference in Phoenix on Thursday, Nov. 12, 2009 at approximately 10 a.m. MST (noon EST).

BioMimetic Therapeutics, Inc. (NASDAQ:BMTI) announced the Company plans to release its financial results for the three and nine months ended September 30, 2009, on Thursday, November 5, 2009 after the close of the market.

BIOLASE Technology, Inc. (NASDAQ:BLTI), the world's leading dental laser company, announced the launch of the Diolase 10™ Diode Laser for therapeutic applications, including temporary pain relief.

Aethlon Medical, Inc. (OTC:AEMD) announced it has initiated a collaborative biomarker discovery program with the Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine and the Sports Legacy Institute (SLI).

ULURU Inc. (NYSE:ULU) announced it has scheduled a conference call to discuss the third quarter ended September 30, 2009 financial results and provide a general business update on Tuesday, November 17, 2009 at 9:00 a.m. Eastern Time.

CNS Response, Inc. (OTC:CNSO) reported the results of a landmark study presented by Charles DeBattista, D.M.H, M.D., at the U.S. Psychiatric and Mental Health Congress.

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,612,199 (the ‘199 patent) entitled “Polymorphic Forms Alpha, Beta, and Gamma of Rifaximin”.

Viriathus Research LLC, an independent research firm, issued an Update Report for Viralytics Limited (OTC: VRACY), a biotechnology company which is developing therapies and drugs for the treatment of cancer in Australia.

Affymax, Inc. (Nasdaq:AFFY) announced the appointment of Hollings C. Renton to the position of chairman of the company’s board of directors effective December 1, 2009.

ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced Jonathan Lewis, MD, PhD, Chief Executive Officer, will present at the 6th Annual Merriman, Curhan, Ford Inventor Summit on Tuesday, November 10, 2009 at 12:20 pm ET at the Soffitel Hotel in New York, NY. Dr. Lewis will provide an overview of the Company and its clinical development programs.

Walgreens (NYSE:WAG), the nation’s largest drugstore chain and industry leader with more than 17,000 certified or licensed immunizers, will begin offering H1N1 injectable vaccines at 18 pharmacies throughout Salt Lake County Thursday.